NPs Basic Information
|
Name |
Palmarumycin CP5
|
| Molecular Formula | C20H18O6 | |
| IUPAC Name* |
(4S,5R,9R)-5,8-dihydroxyspiro[11-oxatricyclo[6.2.1.04,9]undecane-10,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-3-one
|
|
| SMILES |
C1CC2([C@H]3[C@@H]([C@@H]1O)C(=O)CC(C34OC5=CC=CC6=C5C(=CC=C6)O4)O2)O
|
|
| InChI |
InChI=1S/C20H18O6/c21-11-7-8-19(23)18-17(11)12(22)9-15(26-19)20(18)24-13-5-1-3-10-4-2-6-14(25-20)16(10)13/h1-6,11,15,17-18,21,23H,7-9H2/t11-,15?,17+,18-,19?/m1/s1
|
|
| InChIKey |
DPEHGHDGMHDDEP-ABMVIXFTSA-N
|
|
| Synonyms |
Palmarumycin CP5
|
|
| CAS | NA | |
| PubChem CID | 139587906 | |
| ChEMBL ID | NA |
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification: |
|
|
|---|
——————————————————————————————————————————
NPs Species Source
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
NPs Biological Activity
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
NPs Physi-Chem Properties
| Molecular Weight: | 354.4 | ALogp: | 1.5 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 85.2 | Aromatic Rings: | 6 |
| Heavy Atoms: | 26 | QED Weighted: | 0.755 |
——————————————————————————————————————————
NPs ADMET Properties*
ADMET: Absorption
| Caco-2 Permeability: | -4.924 | MDCK Permeability: | 0.00002980 |
| Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.516 |
| Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.064 |
| 30% Bioavailability (F30%): | 0.159 |
——————————————————————————————————————————
ADMET: Distribution
| Blood-Brain-Barrier Penetration (BBB): | 0.855 | Plasma Protein Binding (PPB): | 94.10% |
| Volume Distribution (VD): | 0.68 | Fu: | 4.63% |
——————————————————————————————————————————
ADMET: Metabolism
| CYP1A2-inhibitor: | 0.042 | CYP1A2-substrate: | 0.717 |
| CYP2C19-inhibitor: | 0.032 | CYP2C19-substrate: | 0.785 |
| CYP2C9-inhibitor: | 0.034 | CYP2C9-substrate: | 0.761 |
| CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.275 |
| CYP3A4-inhibitor: | 0.274 | CYP3A4-substrate: | 0.395 |
——————————————————————————————————————————
ADMET: Excretion
| Clearance (CL): | 13.336 | Half-life (T1/2): | 0.352 |
——————————————————————————————————————————
ADMET: Toxicity
| hERG Blockers: | 0.121 | Human Hepatotoxicity (H-HT): | 0.995 |
| Drug-inuced Liver Injury (DILI): | 0.893 | AMES Toxicity: | 0.913 |
| Rat Oral Acute Toxicity: | 0.821 | Maximum Recommended Daily Dose: | 0.531 |
| Skin Sensitization: | 0.42 | Carcinogencity: | 0.073 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
| Respiratory Toxicity: | 0.954 |
——————————————————————————————————————————
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.
Similar Compounds*
Compounds similar to EMNPD with top10 similarity:
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003761 |  |
0.682 | D08CCE |  |
0.239 | ||
| ENC003417 |  |
0.581 | D00JRA |  |
0.231 | ||
| ENC003411 |  |
0.546 | D0PG8O |  |
0.227 | ||
| ENC003416 |  |
0.531 | D06TJJ |  |
0.225 | ||
| ENC001947 |  |
0.526 | D02NSF |  |
0.223 | ||
| ENC003288 |  |
0.515 | D05MQK |  |
0.223 | ||
| ENC003287 |  |
0.515 | D01KQA |  |
0.221 | ||
| ENC003413 |  |
0.495 | D03YVO |  |
0.221 | ||
| ENC003418 |  |
0.495 | D0O6IZ |  |
0.218 | ||
| ENC003412 |  |
0.495 | D04JHN |  |
0.216 | ||